Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2010 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly EBITDA Margin came in at 29.78% in Q1 2026, up 2800.0% year-on-year from 1.03% in Q1 2025, and down 60.42% on a QoQ basis from 18.56% in Q4 2025.
Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 6 years of EBITDA Margin data on file, last reported at 29.78% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 2800.0% year-over-year to 29.78% in Q1 2026; TTM through Mar 2026 was 27.68%, a 10627.0% increase from a year earlier, with the FY2025 full-year figure at 31.31%, up 24508.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 29.78%, down from 18.56% in the prior quarter.
- Over the last five years, EBITDA Margin for MDGL reached as high as 18.56% in Q4 2025 and fell as low as 1110.38% in Q2 2024.
- Historically, EBITDA Margin has averaged 191.28% across 3 years, with a median of 48.73% in 2025.
- Across the five-year window, EBITDA Margin soared 108820 bps in 2025 and jumped 2800 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 64.84% in 2024, then jumped by 71 bps to 18.56% in 2025, then plunged by 60 bps to 29.78% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 29.78% in Q1 2026, 18.56% in Q4 2025, and 39.68% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - | -29.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.78% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -39.68% |
| Jun 30, 2025 | -22.18% |
| Mar 31, 2025 | -57.79% |
| Dec 31, 2024 | -64.84% |
| Sep 30, 2024 | -187.06% |
| Jun 30, 2024 | -1,110.38% |
| Sep 30, 2012 | -29,413.61% |
| Jun 30, 2012 | -19,523.13% |
| Mar 31, 2012 | -9,908.16% |
| Dec 31, 2011 | -8,461.98% |
| Sep 30, 2011 | -734.25% |
| Jun 30, 2011 | -5,691.47% |
| Mar 31, 2011 | -959.41% |
| Dec 31, 2010 | -207.21% |
| Sep 30, 2010 | -302.42% |
| Jun 30, 2010 | -269.17% |